QTTB - Q32 Bio Inc.
IEX Last Trade
43.04
3.800 8.829%
Share volume: 236,506
Last Updated: Fri 30 Aug 2024 09:59:21 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$39.24
3.80
9.68%
Fundamental analysis
12%
Profitability
0%
Dept financing
9%
Liquidity
75%
Performance
10%
Performance
5 Days
10.10%
1 Month
15.98%
3 Months
58.98%
6 Months
162.56%
1 Year
102.99%
2 Year
3.23%
Key data
Stock price
$43.04
DAY RANGE
N/A - N/A
52 WEEK RANGE
$8.24 - $43.50
52 WEEK CHANGE
$1.01
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Arthur Tzianabos
Region: US
Website: https://www.homologymedicines.com/
Employees: 131
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.homologymedicines.com/
Employees: 131
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Recent news